Find Funding Opportunities

Notice Change Foreign Component Eligibility RFA-NS-18-001 Centers Without Walls Collaborative Research the Epilepsies: Functional Evaluation Human Genetic Variants U54)" Notice Number: NOT-NS-18-013 Key Dates Release Date: September 26, 2017 Related Announcements RFA-NS-18-001 Issued National Institute Neurological Disorders Stroke NINDS) Purpose purpose this Notice to change Foreign Component Eligibility RFA-NS-18-001 quot;Centers Without Walls Collaborative Research the Epilepsies: Functional Evaluation Human Genetic Variants U54)" allow Foreign components, defined the NIH Grants Policy Statement.  Section III.1 Eligible Applicants, Eligible Organizations, Foreign Institutions subsection been updated reflect change: Currently: Foreign Institutions Non-domestic non-U.S.) Entities Foreign Institutions) not eligible apply. Non-domestic non-U.S.) components U.S. Organizations not eligible apply. Foreign components, as defined the NIH Grants Policy Statement, not allowed. Modified read: Foreign Institutions Non-domestic non-U.S.) Entities Foreign Institutions) are not eligible apply. Non-domestic non-U.S.) components U.S. Organizations are not eligible apply. Foreign components, as defined the NIH Grants Policy Statement, are allowed. other aspects this Funding Opportunity Announcement remain same. Inquiries Please direct inquiries to: Randall R. Stewart, Ph.D. National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-1917 Email: Randall.Stewart@nih.gov

Notice Change Application Due Dates RFA-NS-18-001 Center Without Walls Collaborative Research the Epilepsies: Functional Evaluation Human Genetic Variants U54)" Notice Number: NOT-NS-18-010 Key Dates Release Date:   September 22, 2017 Related Announcements RFA-NS-18-001 Issued National Institute Neurological Disorders Stroke NINDS) Purpose purpose this Notice to change Key Dates RFA-NS-18-001 Center Without Walls Collaborative Research the Epilepsies: Function Evaluation Human Genetic Variants U54)". Part 1. Overview Information Key Dates Currently Reads: Open Date October 15, 2017 Application Due Date(s) November 15, 2017, 5:00 PM local time applicant organization. types non-AIDS applications allowed this funding opportunity announcement due this date. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. Scientific Merit Review March 10, 2018 Advisory Council Review 2018 Earliest Start Date July 1, 2018 Expiration Date November 16, 2017 Modified read: Open Date December 16, 2017 Application Due Date(s) January 16, 2018, 5:00 PM local time applicant organization. types non-AIDS applications allowed this funding opportunity announcement due this date. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. Scientific Merit Review June 2018 Advisory Council Review August 2018 Earliest Start Date September 2018 Expiration Date January 17, 2018   other aspects this FOA remain same. Inquiries Please direct inquiries to: Randall R Stewart, Ph.D. National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-1917 Email: stewartr@ninds.nih.gov

Notice Intent Publish Funding Opportunity Announcement Countermeasures Against Chemical Threats CounterACT) Research Centers Excellence U54) Notice Number: NOT-NS-18-009 Key Dates Release Date: September 19, 2017 Estimated Publication Date Announcement: December 2017  First Estimated Application Due Date: September 2018 Earliest Estimated Award Date: July 2019  Earliest Estimated Start Date: July 2019  Related Announcements None Issued National Institute Neurological Disorders Stroke NINDS) Purpose National Institute Neurological Disorders Stroke NINDS), intends re-issue Program Announcement Special Review Considerations PAR) solicit applications quot;Countermeasures Against Chemical Threats CounterACT) Research Centers Excellence U54)". goal this initiative to provide support translational research develop therapeutics reducing mortality morbidity caused acute exposures chemical threat agents. Chemical threats toxic chemicals could used a terrorist attack accidentally released industrial production, storage shipping.  scope the research includes target candidate identification characterization, through candidate optimization demonstration in vivo efficacy consistent the product's intended in humans. applicants submitting U54 renewal applications, research under FOA should culminate an optimized lead compound ready advanced development.  www.ninds.nih.gov/counteract a description the NIH CounterACT research program. Notice being provided allow potential applicants sufficient time develop meaningful collaborations responsive projects.  general description the planned FOA provided below. sure follow guidance specific instructions the final published FOA once is released.  Research Initiative Details planned FOA encourage collaborative multidisciplinary investigations, combining expertise toxicology drug discovery development, discover develop new improved therapeutics treating victims acute chemical exposures. NIH CounterACT research program utilize Specialized Center Cooperative Agreements U54) support Research Centers Excellence up 5 years.  Center include several individual research projects scientific administrative cores create interdisciplinary multifaceted research approach. should a unifying well-defined goal problem area research which project relates contributes, thereby producing synergistic research environment allows research effort share resources creative strengths the others. is expectation support inter-related projects collaborating investigators yield results beyond those achievable each project pursued separately without formal interaction among participating investigators. civilian chemical threat spectrum includes chemical warfare agents e.g., sarin), toxic industrial chemicals e.g., cyanide), pesticides e.g., parathion), other chemicals.  agents included the current Department Homeland Security DHS) Chemical Terrorism Risk Assessment CTRA) list, is USG official only will be included the planned FOA.  Therefore, applicants strongly urged contact Scientific/Research staff listed this Notice determine their proposed threat agent(s) of interest the NIH.    Research Center must establish milestones include discrete quantitative goals create or no-go decision points the project. APPLICATIONS NOT BEING SOLICITED THIS TIME. Inquiries Please direct inquiries to: David A. Jett, Ph.D. National Institute Neurological Disorders Stroke, NINDS Telephone: 301-496-6035 Email: jettd@ninds.nih.gov

BRAIN Initiative: Notice Support Research the Fundamental Neurobiology Pain Processing Notice Number: NOT-NS-18-008 Key Dates Release Date: September 12, 2017 Related Announcements None Issued National Institutes Health NIH) National Eye Institute NEI) National Institute Aging NIA) National Institute Alcohol Abuse Alcoholism NIAAA) National Institute Biomedical Imaging Bioengineering NIBIB) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) National Institute Deafness Other Communication Disorders NIDCD) National Institute Drug Abuse NIDA) National Institute Mental Health NIMH) National Institute Neurological Disorders Stroke NINDS) National Center Complementary Integrative Health NCCIH) Purpose Brain Research through Advancing Innovative Neurotechnologies BRAIN) Initiative aimed revolutionizing neuroscience through development application innovative technologies map neural circuits, monitor modulate activity, understand they contribute thoughts, sensations, emotions behavior.  NIH issued variety Funding Opportunity Announcements FOAs) will support projects apply technologies understand neural circuit function the context specific circuits, resulting a diverse portfolio research the fundamental biology nervous system function.  purpose this announcement to notify research community NIH welcomes BRAIN Initiative applications targeting central nervous system nociceptive pain circuits, appropriate the goals requirements specific BRAIN Initiative FOAs.  Pain conditions represent important public health problem NIH continues support research pain pathologies through normal Institute Center appropriations. However, pain nociception also components normal nervous system function, the BRAIN Initiative committed understanding pain circuits along brain circuits underlying sensory, motor, cognitive emotional functions.  is expected the unique opportunities the BRAIN Initiative enable production detailed maps pain circuits, the adoption powerful new tools monitoring modulating pain circuit activity, leading significant advances the understanding pain nociception. a list past open BRAIN Initiative FOAs, https://braininitiative.nih.gov/funding/.  information goals requirements specific BRAIN FOAs, contact Scientific/Program staff listed the text the respective announcements.  Inquiries Please direct inquiries to: James Gnadt, PhD  National Institute Neurological Disorders Stroke NINDS)  Telephone: 301-496-9964  Email: BRAINCircuits@NIH.GOV   

Notice Encourage Eligible NIH BRAIN Initiative Awardees Apply PA-16-288 Research Supplements Promote Diversity Health-Related Research" Notice Number: NOT-MH-17-048 Key Dates Release Date:   September 1, 2017 Related Announcements PA-16-288 RFA-MH-15-200 RFA-MH-15-225 RFA-NS-15-003 RFA-NS-15-004 RFA-NS-15-005 RFA-NS-15-006 RFA-NS-15-008 RFA-EB-15-006 RFA-EY-16-001 RFA-MH-16-750 RFA-MH-16-775 RFA-MH-16-810 RFA-MH-16-815 RFA-NS-16-006 RFA-NS-16-007 RFA-NS-16-008 RFA-NS-16-009 RFA-NS-16-010 RFA-NS-16-011 RFA-NS-16-018 RFA-EB-17-001 RFA-EB-17-002 RFA-EY-17-001 RFA-MH-17-210 RFA-MH-17-215 RFA-MH-17-220 RFA-MH-17-225 RFA-MH-17-230 RFA-MH-17-235 RFA-MH-17-240 RFA-MH-17-245 RFA-MH-17-256 RFA-MH-17-257 RFA-MH-17-260 RFA-NS-17-003 RFA-NS-17-004 RFA-NS-17-005 RFA-NS-17-006 RFA-NS-17-007 RFA-NS-17-014 RFA-NS-17-015 RFA-NS-17-018 RFA-NS-17-019 Issued National Institute Mental Health NIMH) National Eye Institute NEI) National Institute Biomedical Imaging Bioengineering NIBIB) National Institute Neurological Disorders Stroke NINDS) Purpose Notice encourages eligible awardees the BRAIN Initiative community apply administrative supplements response PA-16-288, quot;Research Supplements Promote Diversity Health-Related Research." NIH a strong interest the diversity the NIH-funded workforce NOT-OD-15-053 NOT-OD-15-089 details) encourages institutions diversify student populations enhancing participation individuals groups identified nationally underrepresented the biomedical, clinical, behavioral, social sciences. BRAIN Initiative 2025 report stated quot;the BRAIN Initiative should a catalyst will drive outstanding young people enter area their most creative career stage." NIH diversity supplement offers opportunity existing BRAIN awardees request additional funds train mentor next generation researchers underrepresented groups will contribute advancing goals the BRAIN Initiative. Among U.S. citizens U.S. institutions, percentage neuroscience trainees underrepresented groups declines the graduate 14%) the postdoctoral level 9%), to 5% the neuroscience tenure-stream faculty 2011 Survey Report Neuroscience Departments Programs). Based data the recently published 2015 Survey Earned Doctorates, 15% the U.S. citizens earning PhDs neuroscience neurobiology year from underrepresented groups, suggesting relatively little change the diversity neuroscience graduate students the first half this decade. Program Directors/Principal Investigators PD/PI) active BRAIN Initiative research program grants thus encouraged identify individuals nationally underrepresented groups support mentorship under auspices this administrative supplement. Individuals the identified groups eligible throughout continuum high school the faculty level. activities proposed the supplement application must fall within scope the parent grant, both advance objectives the parent grant support research training professional development the supplement candidate. BRAIN Initiative PIs strongly encouraged incorporate training activities will help prepare supplement candidate conduct rigorous research relevant the goals the BRAIN Initiative 2025 Report. Educational goals the NIH component the BRAIN Initiative BRAIN 2025: Scientific Vision) include acquisition quantitative skills, appropriate and integration newly developed tools, technologies methods developed under BRAIN Initiative, consideration the ethical implications neuroscience research. BRAIN 2025 Report notes individuals should obtain robust grounding quantitative reasoning, principles, techniques during training. special focus training quantitative neuroscience, i.e., theory statistics biologists, exposing physicists, engineers statisticians experimental neuroscience. BRAIN 2025 Report strongly encourages scientists cross traditional areas expertise conduct interdisciplinary research, acknowledges need attract investigators faculty recruits neuroscience quantitative disciplines, e.g., statistics, computer science, physics, mathematics, engineering.   Applicants requested state, the first sentence the Research Strategy, the parent grant awarded a BRAIN Initiative award, to state specific FOA the parent grant e.g., RFA-NS-16-006). Inclusion this information facilitate processing the supplement application.  some cases, diversity supplement be submitted a multiple-PD/PI MPI) BRAIN Initiative award is awarded a foreign institution. Specifically, diversity supplement be submitted the supplement candidate meets eligibility criteria specified PA-16-288, will work a subaward MPI a domestic institution. Potential applicants encouraged confirm eligibility the Program contact listed below.  BRAIN diversity supplement awardees, appropriate the duration their support career stage, strongly encouraged participate annual PD/PI meetings in activities. Applicants request funds, addition the research costs specified PA-16-288, enable supplement candidate attend annual PD/PI meeting the Washington, DC area. request additional funds should reasonable well justified the application.  Before submitting application, applicants encouraged review supplemental guidance BRAIN Initiative diversity supplement applications the NIH BRAIN Initiative web site. Consultation the Program Official the qualifying BRAIN award the individual named under Inquiries below also strongly encouraged confirm candidate eligibility to obtain technical assistance. Supplement applications be evaluated the BRAIN Initiative research training committee, committee Program staff the Institutes Centers participating the NIH BRAIN Initiative.  Applications be considered according the following schedule: Application Due Date                                    Funding Decision October 1, 2017 December 1, 2017              January 30, 2018 December 2, 2017 February 15, 2018          March 31, 2018 February 16, 2018 April 15, 2018                 30, 2018 April 16, 2018 June 15, 2018                       July 30, 2018 tracking purposes, applicants encouraged inform Dr. Nancy Desmond via email BRAIN.Initiative.Training@nih.gov) a diversity supplement application submitted. Please include PD/PI name grant number the subject line this email. Inquiries Please direct inquiries to: Nancy L Desmond, Ph.D. National Institute Mental Health NIMH) Telephone: 301-443-3107 Email: BRAIN.Initiative.Training@nih.gov 

Notice Informational Webinar the NIH Pathway Independence Award K99/R00) Postdoctoral Mentored Career Development Award K01) Notice Number: NOT-NS-18-007 Key Dates Release Date: August 25, 2017 Related Announcements PA-16-193 PAR-17-145 Issued National Institute Neurological Disorders Stroke NINDS) Purpose Notice to inform potential applicants requesting assignment NINDS the NIH Pathway Independence Award K99/R00; PA-16-193) NINDS Postdoctoral Mentored Career Development Award K01; PAR-17-145) an upcoming informational webinar preparing successful applications. NINDS staff discuss components each award, differences between two award mechanisms, the intended postdoctoral audience each award. webinar recommended postdoctoral fellows, faculty are current potentially future mentors postdoctoral fellows, anyone interested learning the NINDS philosophy postdoctoral training funding. addition, current graduate students intend join laboratories postdoctoral fellows strongly encouraged join webinar, NINDS encourages very early application postdoctoral funding. webinar optional not required submission applications.  Webinar Information Informational Webinar Preparing Applications the NIH Pathway Independence Award K99/R00) NINDS Postdoctoral Mentored Career Development Award K01). October 18, 2017, 1:00-3:00 p.m. Eastern Time webinar provide participants information the intent the K99/R00 K01 mechanisms, will discuss NINDS reviewers expecting a successful application.  Please visit following link register the webinar:  https://nih.webex.com/nih/onstage/g.php?MTID=ed4629fcbd9963d7285a77a5f4… registration link available the bottom the page. Inquiries Please direct inquiries to: Letitia Weigand, PhD National Institute Neurological Disorders Stroke NINDS) Email: letitia.weigand@nih.gov

Notice Clarification the Device Requirement BRAIN Initiative: Next-Generation Invasive Devices Recording Modulation the Human Central Nervous System U44)" Notice Number: NOT-NS-18-006 Key Dates Release Date: August 18, 2017 Related Announcements RFA-NS-17-007 Issued National Eye Institute NEI) National Institute Aging NIA) National Institute Alcohol Abuse Alcoholism NIAAA) National Institute Biomedical Imaging Bioengineering NIBIB) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) National Institute Deafness Other Communication Disorders NIDCD) National Institute Drug Abuse NIDA) National Institute Mental Health NIMH) National Institute Neurological Disorders Stroke NINDS) National Center Complementary Integrative Health NCCIH) Purpose purpose this Notice to add language concerning device-based study requirements RFA-NS-17-007. is expected proposed devices include ability synchronize peripheral ambulatory behavioral signals recorded brain signals. current language reads: Part 2.  Full Text Announcement Section 1. Funding Opportunity Description Objectives this FOA projects must two phases, Phase and Phase II, using Fast-track mechanism.  initial Phase will support non-clinical testing toward filing an IDE an SR study obtaining IRB approval an NSR clinical study.  projects start Phase I, the length Phase will depend the maturity the project entry.  Only those Phase projects have met specific criteria below) transition the subsequent Phase II after NIH administrative review.  Phase II support small clinical study. FOA milestone-driven involves NIH program staff's participation developing project plan, monitoring research progress, making go/no-go decisions.  NIH staff also provide assistance academic investigators familiarizing with clinical device development process the criteria needed advance therapeutic leads diagnostics the clinic.  expectations the program in line those industry regards advancing devices through translational development pipeline.  such, inherent high rate attrition expected within program. Scope the FOA U44 Phase Scope Examples Examples studies can proposed during non-clinical Phase include, are limited to: Non-GLP Good Laboratory Practice) animal studies develop surgical techniques relevant the device, define relevant therapeutic parameters, refine device design preparation subsequent GLP testing regulatory approval vitro animal testing meet FDA recognized ISO/ASTM Standards Activities become GMP Good Manufacturing Practice) compliant Activities bring development process under Design Quality Systems Control Device, software firmware design verification validation activities GLP compliant large animal model safety and/or testing an implanted device language been modified now reads: Part 2. Full Text Announcement Section 1. Funding Opportunity Description Objectives this FOA projects must two phases, Phase and Phase II, using Fast-track mechanism.  initial Phase will support non-clinical testing toward filing an IDE an SR study obtaining IRB approval an NSR clinical study.  projects start Phase I, the length Phase will depend the maturity the project entry.  Only those Phase projects have met specific criteria below) transition the subsequent Phase II after NIH administrative review.  Phase II support small clinical study. Proposed next generation devices strongly encouraged incorporate ability synchronize peripheral, ambulatory behavioral data signals.  signals must synchronized real time, analysis be done an online offline manner.  Data does have be stored board the device may streamed out, long it does interfere significantly the naturalistic behavior i.e., participant must be required carry around large personal computer them synchronization occur).  Behavioral signals be those captured a phone GPS, keyboard usage, accelerometer, etc.), smartwatch, related peripheral behavioral capture device. FOA milestone-driven involves NIH program staff's participation developing project plan, monitoring research progress, making go/no-go decisions.  NIH staff also provide assistance academic investigators familiarizing with clinical device development process the criteria needed advance therapeutic leads diagnostics the clinic.  expectations the program in line those industry regards advancing devices through translational development pipeline.  such, inherent high rate attrition expected within program. Scope the FOA U44 Phase Scope Examples studies can proposed during non-clinical Phase include, are limited to: Non-GLP Good Laboratory Practice) animal studies develop surgical techniques relevant the device, define relevant therapeutic parameters, refine device design preparation subsequent GLP testing regulatory approval vitro animal testing meet FDA recognized ISO/ASTM Standards Activities become GMP Good Manufacturing Practice) compliant Activities bring development process under Design Quality Systems Control Device, software firmware design verification validation activities Device, software, firmware design activities related synchronization naturalistic behavioral data neural recordings GLP compliant large animal model safety and/or testing an implanted device other aspects this FOA remain unchanged Inquiries Please direct inquiries to: Nick Langhals, PhD National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-1447 Email: nick.langhals@nih.gov

Notice Clarification the Device Requirement RFA-NS-17-005 BRAIN Initiative: Next-Generation Invasive Devices Recording Modulation the Human Central Nervous System UG3/UH3)" Notice Number: NOT-NS-18-004 Key Dates Release Date: August 18, 2017 Related Announcements RFA-NS-17-005 Issued National Eye Institute NEI) National Institute Aging NIA) National Institute Alcohol Abuse Alcoholism NIAAA) National Institute Biomedical Imaging Bioengineering NIBIB) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) National Institute Deafness Other Communication Disorders NIDCD) National Institute Drug Abuse NIDA) National Institute Mental Health NIMH) National Institute Neurological Disorders Stroke NINDS) National Center Complementary Integrative Health NCCIH) Purpose purpose this Notice to add language concerning device-based study requirements RFA-NS-17-005.  is expected proposed devices include ability synchronize peripheral ambulatory behavioral signals recorded brain signals. current language reads: Part 2.  Full Text Announcement Section 1. Funding Opportunity Description Objectives this FOA projects must two phases, UG3 UH3.  initial UG3 phase support nonclinical testing support filing an IDE an SR study to obtain IRB approval an NSR clinical study.  projects start the UG3 phase, the length the UG3 phase depend the maturity the project entry.  Only those UG3 projects have met specific criteria below) transition the subsequent UH3 phase after NIH administrative review.  UH3 phase support small clinical study.  Projects which only clinical phase proposed should submitted under RFA-NS-17-006, utilizes UH3 activity code. FOA milestone-driven involves NIH program staff's participation developing project plan, monitoring research progress, making go/no-go decisions.  NIH staff also provide assistance academic investigators familiarizing with clinical device development process the criteria needed advance therapeutic leads diagnostics the clinic.  expectations the program in line those industry regards advancing devices through translational development pipeline.  such, inherent high rate attrition expected within program. Scope the FOA UG3 Scope Examples studies can proposed during non-clinical phase include, are limited to: Non-GLP Good Laboratory Practice) animal studies develop surgical techniques relevant the device, define relevant therapeutic parameters, refine device design preparation subsequent GLP testing regulatory approval vitro animal testing meet FDA recognized ISO/ASTM Standards Activities become GMP Good Manufacturing Practice) compliant Activities bring development process under Design Quality Systems Control Device, software firmware design verification validation activities GLP compliant large animal model safety and/or testing an implanted device language been modified now reads: Part 2. Full Text Announcement Section 1. Funding Opportunity Description Objectives this FOA projects must two phases, UG3 UH3.  initial UG3 phase support nonclinical testing support filing an IDE an SR study to obtain IRB approval an NSR clinical study.  projects start the UG3 phase, the length the UG3 phase depend the maturity the project entry.  Only those UG3 projects have met specific criteria below) transition the subsequent UH3 phase after NIH administrative review.  UH3 phase support small clinical study.  Projects which only clinical phase proposed should submitted under RFA-NS-17-006, utilizes UH3 activity code. Proposed next generation devices strongly encouraged incorporate ability synchronize peripheral, ambulatory behavioral data signals.  signals must synchronized real time, analysis be done an online offline manner.  Data does have be stored board the device may streamed out, long it does interfere significantly the naturalistic behavior i.e., participant must be required carry around large personal computer them synchronization occur).  Behavioral signals be those captured a phone GPS, keyboard usage, accelerometer, etc.), smartwatch, related peripheral behavioral capture device. FOA milestone-driven involves NIH program staff's participation developing project plan, monitoring research progress, making go/no-go decisions.  NIH staff also provide assistance academic investigators familiarizing with clinical device development process the criteria needed advance therapeutic leads diagnostics the clinic.  expectations the program in line those industry regards advancing devices through translational development pipeline.  such, inherent high rate attrition expected within program. Scope the FOA UG3 Scope Examples studies can proposed during non-clinical phase include, are limited to: Non-GLP Good Laboratory Practice) animal studies develop surgical techniques relevant the device, define relevant therapeutic parameters, refine device design preparation subsequent GLP testing regulatory approval vitro animal testing meet FDA recognized ISO/ASTM Standards Activities become GMP Good Manufacturing Practice) compliant Activities bring development process under Design Quality Systems Control nbsp;Device, software firmware design verification validation activities Device, software, firmware design activities related synchronization naturalistic behavioral data neural recordings GLP compliant large animal model safety and/or testing an implanted device other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: Nick Langhals, PhD National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-1447 Email: nick.langhals@nih.gov

Notice Extend Expiration Date PAR-15-195 NeuroNEXT Infrastructure Resource Access X01)" Notice Number: NOT-NS-18-003 Key Dates Release Date: August 14, 2017 Related Announcements PAR-15-195 Issued National Institute Neurological Disorders Stroke NINDS) Purpose purpose this Notice to inform interested applicants the expiration date the Funding Opportunity Announcement FOA) PAR-15-195 quot;NeuroNEXT Infrastructure Resource Access X01)" be extended one receipt cycle.  FOA expires March 13, 2018. Key Dates Table updated accordingly: Part 1. Overview Information Key Dates Currently reads: Application Due Date(s) Applications accepted continuous receipt, 5:00 PM local time applicant organization. types non-AIDS applications allowed this funding opportunity announcement due these dates: Council Round: Receipt Window: November 13 - March 12 Council Round: October Receipt Window: March 13 - July 12 Council Round: January Receipt Window: July 13 - November 12 Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. Expiration Date November 13, 2017 Modified read Application Due Date(s) Applications accepted continuous receipt, 5:00 PM local time applicant organization. types non-AIDS applications allowed this funding opportunity announcement due these dates: Council Round: Receipt Window: November 13 - March 12 Council Round: October Receipt Window: March 13 - July 12 Council Round: January Receipt Window: July 13 - November 12 Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. Expiration Date March 13, 2018 other aspects the FOA remain unchanged. Inquiries Please direct inquiries to: Codrin Lungu, MD National Institute Neurological Disorders Stroke NINDS) Telephone: 301) 496-9135 Email: Codrin.Lungu@nih.gov nbsp;

NINDS Small Business Innovation Research SBIR) Small Business Technology Transfer STTR) R41, R42, R43, R44) Notice: Programmatic Priorities Notice Number: NOT-NS-18-002 Key Dates Release Date: August 10, 2017 Related Announcements None Issued National Institute Neurological Disorders Stroke NINDS) Purpose purpose this Notice to alert field program priorities relevant the SBIR STTR programs the National Institute Neurological Disorders Stroke NINDS). SBIR STTR programs include following objectives: stimulate technological innovation; meet federal research development R&D) needs; increase private sector commercialization innovations developed through federal R&D funding; foster encourage participation innovation entrepreneurship socially economically disadvantaged persons women-owned small businesses. NINDS uses SBIR STTR programs achieve mission the institute supporting innovative ideas different stages development, including applied bench research, translational research, early stage clinical trials. Notice underscores high programmatic priority given research seeks achieve goals the SBIR STTR programs. NINDS priorities given meritorious research proposals the greatest potential advance NINDS mission https://www.ninds.nih.gov/About-NINDS/Who-We-Are/Mission). NINDS especially interested in: 1) Novel innovative technologies are new the SBIR STTR programs. 2) Technologies coming the SBIR STTR programs their first indication market opportunity. 3) Companies applicants are new the SBIR STTR programs. 4) NINDS Cooperative Agreement U44) Translational Programs. NINDS specific translational programs utilize SBIR cooperative agreement mechanism U44). eligible, companies encouraged apply through programs. NINDS SBIR STTR funding decisions based a combination factors: 1) potential high impact advancing NINDS mission the programmatic priorities described this Notice; 2) potential commercialization; 3) portfolio balance determine whether similar projects already funded, search NIH Reporter http://projectreporter.nih.gov/reporter.cfm); 4) quality the previous performance the applicant and/or company the SBIR and/or STTR program, including evidence Phase III activities; 5) Phase II applicants, results the Phase I; 6) peer review scores critiques; 7) availability funds. Inquiries Please direct inquiries to: Stephanie Fertig, M.B.A. National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-1779 Email: fertigs@ninds.nih.gov